Table 3.
Primary endpoint and other study endpoints of the 2 groups.
| Chemical prophylaxis | Mechanical prophylaxis | p value | |||||
|---|---|---|---|---|---|---|---|
| N | Events | N | Events | ||||
| DVTonly (n/%) | 329 | 1 | 0.3% | 419 | 12 | 2.9% | 0.008 |
| PE event (n/%) | 329 | 0 | 0.0% | 419 | 1 | 0.2% | 0.375 |
| DVT/PE (n/%) | 329 | 1 | 0.3% | 419 | 13 | 3.1% | 0.005 |
| ICU LOS in days (median/IQR) | 329 | 7.33 | 4.93–11.86 | 419 | 6.85 | 4.52–11.81 | 0.380 |
| Hospital LOS in days (median/IQR) | 329 | 15 | 9.5–24 | 419 | 13 | 8–23 | 0.007 |
| MV days (Median/IQR) | 329 | 5.2 | 3.1–9.98 | 419 | 5.21 | 3.03–9.35 | 0.908 |
| PRBC transfusion (n/%) | 329 | 79 | 24.0% | 419 | 155 | 37.0% | 0.000 |
| PRBC units (median/IQR) | 329 | 2 | 1–3 | 155 | 4 | 2–6 | 0.000 |
| Mortality (n/%) | 329 | 113 | 34.3% | 419 | 212 | 50.6% | 0.000 |